Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 83% Improvement Relative Risk ICU admission 44% Hospitalization 4% c19hcq.org Million et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Retrospective 10,429 patients in France Lower mortality with HCQ+AZ (p=0.0007) Million et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2203116 Favors HCQ Favors control
Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric Retrospective Cohort Study
Million et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2203116 (date from earlier preprint)
Million et al., Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric.., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2203116 (date from earlier preprint)
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 10,429 outpatients in France, 8,315 treated with HCQ+AZ a median of 4 days from symptom onset, showing significantly lower mortality with treatment.
risk of death, 83.0% lower, HR 0.17, p < 0.001, treatment 5 of 8,315 (0.1%), control 11 of 2,114 (0.5%), NNT 217, adjusted per study.
risk of ICU admission, 44.0% lower, HR 0.56, p = 0.18, treatment 17 of 8,315 (0.2%), control 7 of 2,114 (0.3%), NNT 789, adjusted per study.
risk of hospitalization, 4.0% lower, HR 0.96, p = 0.77, treatment 214 of 8,315 (2.6%), control 64 of 2,114 (3.0%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Million et al., 27 May 2021, retrospective, France, peer-reviewed, 28 authors, average treatment delay 4.0 days, dosage 200mg tid days 1-10, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Medicine Original Research Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients Matthieu MILLION1, *, Jean-Christophe LAGIER1 , Hervé TISSOT-DUPONT1 , Isabelle RAVAUX1 , Catherine DHIVER1 , Christelle TOMEI1 , Nadim CASSIR1 , Léa DELORME2 , Sébastien CORTAREDONA2 , Sophie AMRANE2 , Camille AUBRY2 , Karim BENDAMARDJI1 , Cyril BERENGER2 , Barbara DOUDIER1 , Sophie EDOUARD1 , Marie HOCQUART2 , Morgane MAILHE1 , Coralie PORCHETO1 , Piseth SENG1 , Catherine TRIQUET1 , Stéphanie GENTILE3 , Elisabeth JOUVE3 , Audrey GIRAUD-GATINEAU2 , Herve CHAUDET2 , Laurence CAMOIN-JAU4 , Philippe COLSON1 , Philippe GAUTRET2 , Pierre-Edouard FOURNIER2 , Baptiste MAILLE5 , Jean-Claude DEHARO5 , Paul HABERT6 , Jean-Yves GAUBERT6 , Alexis JACQUIER6 , Stéphane HONORE7 , Katell GUILLON-LORVELLEC1 , Yolande OBADIA2 , Philippe PAROLA2 , Philippe BROUQUI1 , Didier RAOULT1 1 IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD), Reviews in Cardiovascular Unité Microbes Evolution Phylogénie et Infections (MEPHI),13005 Marseille, France 2 IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD), Unité Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), Service de santé des armées (SSA), 13005 Marseille, France 3 EA 3279: CEReSS - Health Service Research and Quality of Life Center, Service d'Evaluation Médicale, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France 4 Laboratoire D'Hématologie, Hôpital de La Timone, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France 5 Service de Cardiologie, Centre Hospitalier Universitaire La Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Univ, C2VN, 13005 Marseille, France 6 Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, Aix Marseille Univ, LIIE, CERIMED, 13005 Marseille, France 7 Service de Pharmacie, Hôpital Timone, Laboratoire de Pharmacie Clinique, Aix Marseille Université AP-HM, 13005 Marseille, France *Correspondence: matthieu.million@gmail.com (Matthieu MILLION) DOI:10.31083/j.rcm2203116 This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). Submitted: 10 August 2021 Revised: 27 August 2021 Accepted: 30 August 2021 Published: 24 September 2021 We evaluated the age-specific mortality of unselected adult outpatients infected with SARS-CoV-2 treated early in a dedicated COVID19 day hospital and we assessed whether the use of hydroxychloroquine (HCQ) + azithromycin (AZ) was associated with improved survival in this cohort. A retrospective monocentric cohort study was conducted in the day hospital of our center from March to December 2020 in adults with PCR-proven infection who were treated as outpatients with a standardized protocol. The primary endpoint was 6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. Among 10,429 patients (median age, 45 [IQR 32–57] years; 5597 [53.7%] women), 16 died (0.15%). The infection fatality rate was 0.06% among the 8315 patients treated with HCQ+AZ. No deaths occurred among the 8414 patients younger than 60 years. Older age and male sex were associated with a higher risk of death, ICU transfer, and..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit